Welcome to our dedicated page for Wave Life Scienc SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences Ltd. filed a current report noting it has issued a press release titled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The company highlights regulatory plans around its WVE-006 program for this genetic condition.
The press release is furnished as Exhibit 99.1 and incorporated by reference, while a cover page interactive data file is included as Exhibit 104. The report is signed by President and Chief Executive Officer Paul B. Bolno, M.D.
Wave Life Sciences Ltd. reported a preliminary, unaudited estimate of its cash and cash equivalents, stating that this balance was approximately $602 million as of December 31, 2025. This estimate was included in a press release and an updated corporate presentation made available to the investment community.
The company emphasized that this cash figure is subject to change once full audited financial statements for the year are completed, and any adjustments could be material. Wave Life Sciences also furnished its updated corporate presentation and the related press release as exhibits to this report, while specifying that these materials are being furnished rather than filed for securities law purposes.
Wave Life Sciences Ltd. executive Chris Francis reported an option exercise and share sales in a Form 4. On January 2, 2026, Francis exercised 9,375 share options at an exercise price of $3.14 per share, receiving the same number of ordinary shares. On the same day, he sold 8,080 ordinary shares at a weighted-average price of $15.92 per share and 1,295 ordinary shares at a weighted-average price of $16.70 per share, in multiple transactions within disclosed price ranges. After these transactions, Francis directly owned 25,000 ordinary shares. The filing notes that these fully vested options and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025.
GSK plc, through its wholly owned subsidiary Glaxo Group Limited, reported buying 1,470,000 ordinary shares of Wave Life Sciences Ltd. on 12/11/2025 at a price of $19 per share.
After this transaction, the reporting person beneficially owned 18,245,691 Wave Life Sciences ordinary shares, held indirectly via Glaxo Group Limited. The report reflects GSK plc’s role as a shareholder in Wave Life Sciences rather than a change in GSK plc’s own financial results.
Wave Life Sciences Ltd. is conducting a primary offering of 15,789,475 ordinary shares and pre-funded warrants to purchase 2,631,578 ordinary shares. The securities are priced at $19.00 per share and $18.9999 per pre-funded warrant, for a total public offering price of $349,999,744, with estimated net proceeds of approximately $328.4 million after underwriting discounts and expenses. The underwriters have a 30‑day option to buy up to an additional 2,763,157 ordinary shares, which would lift net proceeds to approximately $377.8 million.
The company plans to use the cash primarily to accelerate Phase 2 trials of WVE‑007, its INHBE GalNAc‑siRNA candidate for obesity, and for general corporate purposes. Recent interim Phase 1 data for WVE‑007 showed a single 240 mg dose produced a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat and a 3.2% increase in lean mass at three months, along with durable serum Activin E reductions greater than 75%. As of September 30, 2025, 160,288,481 ordinary shares were outstanding, rising to 176,077,956 on an as‑adjusted basis giving effect to this offering, and new investors face immediate net tangible book value dilution of $16.39 per share.
Wave Life Sciences is raising capital through an underwritten public offering of 15,789,475 ordinary shares at $19.00 per share, plus pre-funded warrants to purchase up to 2,631,578 shares at $18.9999 each, and 2,763,157 additional shares purchased by the underwriters.
The transaction is expected to generate approximately $402.5 million in gross proceeds before fees, with all securities sold by the company. Including these proceeds, Wave Life Sciences expects its cash and cash equivalents to fund operations into the third quarter of 2028 and anticipates having approximately 187,693,059 ordinary shares outstanding after closing.
Wave Life Sciences Ltd. director reports option exercise and share sale. On December 8, 2025, director Adrian Rawcliffe exercised 42,000 share options for Wave Life Sciences ordinary shares at an exercise price of $5.97 per share. On the same day, he sold 42,000 ordinary shares at a sale price of $15.00 per share.
Following these transactions, Rawcliffe directly held 12,700 ordinary shares and no remaining share options. The filing states that the option exercise and related sales were carried out under a Rule 10b5-1 trading plan adopted on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade on a scheduled basis.
Wave Life Sciences Ltd. director reported stock transactions in company ordinary shares. On 12/08/2025, the insider exercised share options with an exercise price of $5.97 per share and sold 7,000 shares at $13 and another 7,000 shares at $14.
After these transactions, the reporting person directly owned 44,930 ordinary shares. The filing also shows share options to buy Wave Life Sciences ordinary shares at $5.97 that are fully vested and were transacted under a Rule 10b5-1 trading plan adopted on March 13, 2025.
Wave Life Sciences Ltd. director Gregory L. Verdine reported sales of company stock. On 12/08/2025, he sold 12,020 ordinary shares at a weighted-average price of $13.09 per share and 7,980 ordinary shares at a weighted-average price of $14.05 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After these transactions, Verdine directly owned 275,217 ordinary shares of Wave Life Sciences. The price ranges for the sales were $12.75–$13.74 and $13.75–$14.70 per share, respectively.
Wave Life Sciences Ltd. executive reports option exercises and share sales. On December 8, 2025, a senior officer of Wave Life Sciences exercised multiple vested share options with exercise prices ranging from $2.83 to $10.48 per ordinary share and sold the resulting shares on the same day. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025.
Following the reported option exercises and sales, the officer directly holds 25,000 ordinary shares. The filing notes that certain sale prices are reported on a weighted-average basis, including averages of $14.556 and $14.195 per share, and the officer has agreed to provide full pricing details upon request.